Profile: Novo Nordisk A/S (NVO)
28 Oct 2016
Novo Nordisk A/S, incorporated on November 28, 1931, is a healthcare company. The Company is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company's business segments include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1), other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. The biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy.
The Company offers a range of diabetes product, including new generation insulins and a portfolio of modern insulin. It provides Saxenda, which is a product to treat obesity and is available in Denmark, Italy and Canada. The Company's other products/compounds include Xultophy, Semaglutide (NN9535), Faster-acting insulin aspart (NN1218), N9-GP (NN7999), N8-GP (NN7088) and NN8640 Once-weekly human growth hormone. Xultophy is indicated for Type 2 diabetes and it has completed its Phase III clinical trials. Semaglutide (NN9535) is indicated for Type 2 diabetes and it is being evaluated in Phase III clinical trials. Faster-acting insulin aspart (NN1218) is indicated for Type 1 and Type 2 diabetes and it has completed its Phase III clinical trials. N9-GP (NN7999) is indicated for Hemophilia B and it has completed its Phase III clinical trials. N8-GP (NN7088) is indicated for Hemophilia A and it has completed its Phase III clinical trials. NN8640 Once-weekly human growth hormone is indicated for growth disorder and it is being evaluated in Phase III clinical trials.
The Company markets its products markets its products in over 180 countries. The Company's insulin and other pharmaceutical products are marketed and distributed through subsidiaries, distributors and independent agents with respective of geographical areas. The Company operates in various markets, including North America, China, Japan and European countries, as well as in Saudi Arabia, Algeria, Turkey, Argentina, Australia, India, Brazil, Iran and Russia.
Novo Nordisk A/S
Novo Alle 1
Company Web Links
- Novo Nordisk slashes long-term growth view on U.S. market woes
- UPDATE 4-Novo Nordisk slashes long-term growth view on U.S. market woes
- Novo Nordisk will stay in U.S. insulin market 'whatever it costs': CEO
- Novo Nordisk will stay in U.S. insulin market "whatever it costs" - CEO
- European shares slip as earnings disappointments bite, Novo slides